Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020205627 - USE OF BIOMARKER IN CANCER THERAPY

Publication Number WO/2020/205627
Publication Date 08.10.2020
International Application No. PCT/US2020/025472
International Filing Date 27.03.2020
IPC
C12Q 1/68 2018.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
C12Q 1/6841 2018.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6813Hybridisation assays
6841In situ hybridisation
C12Q 1/686 2018.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6844Nucleic acid amplification reactions
686Polymerase chain reaction
A61K 31/519 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • RAIN THERAPEUTICS INC. [US]/[US]
Inventors
  • TIRUNAGARU, Vijaya
Agents
  • FARMER, J. Dean
  • WESPE, Daniel
  • DUNNE, Christine
Priority Data
62/826,06229.03.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) USE OF BIOMARKER IN CANCER THERAPY
(FR) UTILISATION DE BIOMARQUEUR DANS LA THÉRAPIE DU CANCER
Abstract
(EN)
In certain aspects, provided herein is a method of treating or preventing a cancer in a subject in need thereof, wherein the method comprises determining the level of STEAP4 expression in cancer cells to predict whether the cancer cells would be responsive to treatment by a HAP.
(FR)
Dans certains aspects, la présente invention concerne un procédé de traitement ou de prévention d'un cancer chez un sujet en ayant besoin, le procédé comprenant la détermination du niveau d'expression de STEAP4 dans des cellules cancéreuses pour prédire si les cellules cancéreuses sont sensibles au traitement par un HAP.
Latest bibliographic data on file with the International Bureau